AT69476B - Process for the production of therapeutically valuable bactericidal preparations. - Google Patents

Process for the production of therapeutically valuable bactericidal preparations.

Info

Publication number
AT69476B
AT69476B AT69476DA AT69476B AT 69476 B AT69476 B AT 69476B AT 69476D A AT69476D A AT 69476DA AT 69476 B AT69476 B AT 69476B
Authority
AT
Austria
Prior art keywords
production
therapeutically valuable
silver
preparations
bactericidal preparations
Prior art date
Application number
Other languages
German (de)
Inventor
Albert Von Dr Mueller
Original Assignee
Albert Von Dr Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Von Dr Mueller filed Critical Albert Von Dr Mueller
Application granted granted Critical
Publication of AT69476B publication Critical patent/AT69476B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Gewinnung therapeutisch wertvoller bakterizider Präparate. 
 EMI1.1 
 Stoffe hat noch nicht stattgefunden, obgleich die Zahl der in der Medizin   verwendeter   Silberpräparate eine sehr grosse ist. 



   Farbstoffe   der Thioningruppe,   speziell das Methylenblau (salzsaures   Tetramethyithionm)   finden vielseitige Verwendung als Heilmittel bei Infektionskrankheiten und   Geschwülsten.   



   Es wurde nun die überraschende Entdeckung gemacht, dass die Farbstoffe der Thioningruppe mit Silbersalzen gut ausgeprägte   Doppe1verbindungen   liefern, welche ganz hervorragende antiseptische und bakterizide Wirkungen entfalten, in so geringen   Mengen, dal   keine Schädigung des menschlichen oder tierischen Organismus damit verbunden ist. 



   Die starke heilkräftige Wirkung der neuen Präparate beruht offenbar einerseits auf dem sehr hohen Gehalt an Silber   (Methylenblausilbernitrat   enthält über   20%   Ag), das 
 EMI1.2 
 der   Thioninfarbsto : ffe.   



   Dass diese, vom medizinischen Standpunkt aus, in der Theorie sehr wünschenswerte Kombination von Silber mit Thioninfarbstoffen praktisch durchführbar war, und dass das gewonnene Produkt auch die   erwünschten   Eigenschaften hatte, bedurfte der Feststellung durch umfangreiche Versuche. 



   Beispiel. 



   32 Teile reinstes Methylenblau werden in warmem Wasser gelöst und mit einer warmen Lösung von 14 g Silbernitrat in 50 Teilen Wasser vermischt. 



   Das ausgeschiedene Chlorsilber wird abfiltriert. Die klare Lösung wird zum Sieden erhitzt, wieder mit einer Lösung von 14 g Silbernitrat vermischt und bis auf etwa 1/20 ihres ursprünglichen Volumens eingedampft. Die Kristalle werden dann von der Lauge getrennt. in heissem Wasser gelöst, von einer geringen Menge nachträglich ausgeschiedenem Chlorsilber durch Filtration befreit und durch Einengen der Lösung wieder abgeschieden. 



   Man erhält bräunlich grüne Kristalle von Methylenblausilher mit   22'880/0 Ag,   theoretisch   23'78% Ag.   



   Das Silbernitrat kann auch durch andere Silbersalze, z. B. die äquivalente Menge Silberzitrat, ersetzt werden. 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 



  Process for the production of therapeutically valuable bactericidal preparations.
 EMI1.1
 Substance has not yet taken place, although the number of silver preparations used in medicine is very large.



   Dyes of the thionine group, especially methylene blue (hydrochloric acid tetramethylithione) are used in many ways as remedies for infectious diseases and tumors.



   The surprising discovery has now been made that the dyes of the thionine group with silver salts provide well-defined double compounds which have excellent antiseptic and bactericidal effects, in such small quantities that they do not damage the human or animal organism.



   The strong curative effect of the new preparations is apparently based on the one hand on the very high content of silver (methylene blue silver nitrate contains over 20% Ag), the
 EMI1.2
 the thionine dye: ffe.



   That this combination of silver with thionine dyes, which is theoretically very desirable from a medical point of view, was feasible in practice, and that the product obtained also had the desired properties, had to be established through extensive experiments.



   Example.



   32 parts of the purest methylene blue are dissolved in warm water and mixed with a warm solution of 14 g of silver nitrate in 50 parts of water.



   The precipitated silver chlorine is filtered off. The clear solution is heated to boiling, mixed again with a solution of 14 g of silver nitrate and evaporated to about 1/20 of its original volume. The crystals are then separated from the liquor. dissolved in hot water, freed from a small amount of subsequently precipitated silver chlorine by filtration and deposited again by concentrating the solution.



   Brownish green crystals of methylene blue silver with 22,880 / 0 Ag, theoretically 23,78% Ag are obtained.



   The silver nitrate can also be replaced by other silver salts, e.g. B. the equivalent amount of silver citrate to be replaced.

** WARNING ** End of DESC field may overlap beginning of CLMS **.

 

Claims (1)

PATENT-ANSPRUCH : Verfahren zur Gewinnung therapeutisch wertvoller bakterizider Präparate, darin bestehend, dass man Verbindungen der Farbstoffe der Thioningruppe mit Silbersalzen herstellt. **WARNUNG** Ende CLMS Feld Kannt Anfang DESC uberlappen**. PATENT CLAIM: Process for obtaining therapeutically valuable bactericidal preparations, consisting in producing compounds of the dyes of the thionine group with silver salts. ** WARNING ** End of CLMS field may overlap beginning of DESC **.
AT69476D 1913-07-09 1913-07-09 Process for the production of therapeutically valuable bactericidal preparations. AT69476B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT69476T 1913-07-09

Publications (1)

Publication Number Publication Date
AT69476B true AT69476B (en) 1915-07-26

Family

ID=3591294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT69476D AT69476B (en) 1913-07-09 1913-07-09 Process for the production of therapeutically valuable bactericidal preparations.

Country Status (1)

Country Link
AT (1) AT69476B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2277908C1 (en) * 2005-11-25 2006-06-20 Закрытое акционерное общество "БиоАргоФарм" Water soluble agent having antiviral activity based on silver compound with cystine and method for production thereof
RU2390343C1 (en) * 2008-12-15 2010-05-27 Закрытое акционерное общество "БиоАргоФарм" Water-soluble antiviral and immunomodulatiory drug based on ionic silver and methylene blue compound and method for preparing thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2277908C1 (en) * 2005-11-25 2006-06-20 Закрытое акционерное общество "БиоАргоФарм" Water soluble agent having antiviral activity based on silver compound with cystine and method for production thereof
WO2007061337A1 (en) * 2005-11-25 2007-05-31 Zakrytoe Aktsionernoe Obschestvo 'bioargofarm' Water-soluble antiviral agent based on silver-cistine compound and method of preparing thereof
RU2390343C1 (en) * 2008-12-15 2010-05-27 Закрытое акционерное общество "БиоАргоФарм" Water-soluble antiviral and immunomodulatiory drug based on ionic silver and methylene blue compound and method for preparing thereof

Similar Documents

Publication Publication Date Title
AT69476B (en) Process for the production of therapeutically valuable bactericidal preparations.
DE2148986C3 (en) Salts of chondroitin sulfuric acid with carboxymethyl-trimethylammonium hydroxide, process for their preparation and pharmaceuticals containing these compounds
AT100211B (en) Process for the preparation of new organic arsenic compounds.
AT132570B (en) Process for the production of primula saponin from primula species.
AT147483B (en) Process for the preparation of compounds of methyl N-methyltetrahydronicotinate.
AT203633B (en) Process for the preparation of injectable solutions from royal jelly
DE950027C (en) Process for the preparation of injectable extracts of horse chestnut
DE519531C (en) Process for the production of an easily water-soluble, colloidal silver-tannin-protein compound
DE505062C (en) Process for the production of drugs for organ or. tissue-specific treatment of diseases of the human and animal body
AT203000B (en) Process for the preparation of new salts of 4,6-dioxyisophthalic acid and 5-halogen (especially 5-iodine) - 4,6-dioxyisophthalic acid
AT233575B (en) Process for the preparation of new piperazine salts
EP0414895A1 (en) OROTATE OF $g(a)-AMINO-$g(b)-PHENYL-BUTYRIC ACID
AT38550B (en) Process for the production of a tannin-silver-protein compound which is insoluble in gastric juice and sparingly soluble in intestinal juice.
AT263801B (en) Process for the preparation of the new lactone of 2-allyl-2- (β-oxypropyl) -malonic aciduride
AT87644B (en) Process for the preparation of compounds of yohimbine containing arsenic.
DE576445C (en) Process for the production of primula acid (primula saponin) from primula species
DE544667C (en) Process for the preparation of 2-oxy-3-aminopyridine-5-arsic acid
AT101486B (en) Process for the production of an acidic, crystallized saponin from Primula species.
AT123401B (en) Process for the preparation of 3.3&#39;-dichloro-4.4&#39;-dioxy-5.5&#39;-bisacylaminoarsenobenzenes.
AT319934B (en) VZH OF THE NEW 5-N-PYRRYLSALICYLIC ACID AND ITS SALTS
AT55447B (en) Process for the preparation of metal salts of guaiacol and its homologues.
AT268293B (en) Process for the preparation of the new compounds 2-sulfanilamido-pyrazine-4-oxide or 2-sulfanilamido-pyrazine-1-oxide
DE957160C (en) Process for the production of biologically active preparations
DE866229C (en) Process for the preparation of Cero-p-amidobenzene-p-oxy-benzylsulfurea
AT116718B (en) Process for the preparation of β-substitution products of pyridine.